Novo Nordisk has filed 111 lawsuits in 32 states to stop the sale of dangerous, mislabeled, or impurity-laden knockoff semaglutide drugs. Feel unsure about the market’s next move? Copy trade ...

Novo Nordisk scored a huge legal victory that largely restricts compounding pharmacies from marketing or selling cheaper, unapproved versions of the drugmaker's blockbuster weight loss drug Wegovy ...

In a move which could shake up the diabetes market, Novo Nordisk is discontinuing the country’s largest selling insulin, Human Mixtard, among other older insulin brands in India. Human Mixtard ...

"FDA's determination was based on a thorough review of Novo Nordisk's stable and growing supply of these important FDA-approved medicines. With the end of the shortage of Wegovy and Ozempic ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.

Novo Nordisk (NVO) won a key case Thursday to stop some compounding pharmacies from selling knockoff versions of its blockbuster GLP-1 drugs. But it won't end all compounding offerings.

Novo Nordisk will invest around $1 billion to expand its production site in Montes Claros, Brazil, marking one of the largest pharmaceutical investments in the nation’s history. The company’s ...

Carter Worth, Worth Charting, talks technicals on Morgan Stanley and Novo Nordisk. Trump Signs Executive Order To Change College Accreditation What is the most American-made car? Trump Shoots Down ...

Novo Nordisk (NYSE: NVO), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another ...

Novo Nordisk A/S (NVO) is a high-quality biopharma company that has been a growth play well before its recent obesity drug hit. Shares were hyped a while ago, but have now declined so much that ...

In this article, we are going to take a look at where Novo Nordisk A/S (NYSE:NVO) stands against other top falling stocks with unusual volume. Uncertainty around tariffs and macroeconomic ...